Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

References

Page 1

	Year	Citations
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus New England Journal of Medicine	1993	24.5K
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent Joseph Keane, Sharon K. Gershon, Robert P. Wise, New England Journal of Medicine	2001	3.7K
Standards of Medical Care in Diabetes—2008 Diabetes Care Diabetes ManagementHealth PolicyDiabetesDiabetes ComplicationsDiabetes Mellitus	2007	1.4K
Pathologic Anatomy of the Pancreas in Juvenile Diabetes Mellitus W Gepts Diabetes Gross AnatomyPancreatic Fluid CollectionMedicineInsulin ManagementDiabetes	1965	1.3K
Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus Kevan C. Herold, William Hagopian, Julie Auger, New England Journal of Medicine	2002	1.2K
Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes Bart Keymeulen, Evy Vandemeulebroucke, Anette G. Ziegler, New England Journal of Medicine	2005	1.1K
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease Gert Van Assche, Marc Van Ranst, Raf Sciot, New England Journal of Medicine Rheumatoid DisorderAutoimmune DiseaseMedicineImmunodeficienciesImmunology	2005	1.1K
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab Annette Langer‐Gould, Scott W. Atlas, Ari Green, New England Journal of Medicine VasculitisNeurological DisorderImmunodeficienciesImmunologyPathology	2005	1K
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active‐surveillance report Juan J. Gómez‐Reino, Loreto Carmona, Vicente Rodríguez Valverde, Arthritis & Rheumatism	2003	1K
Business Information Endocrine Practice	2007	698

Page 1